Invivyd Stock Price, News & Analysis

Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company, announced that CEO David Hering will present at H.C. Wainwright's BioConnect Investor Conference on May 2, 2023, at 4:00 p.m. ET, held at Nasdaq World Headquarters in New York. The presentation aims to discuss Invivyd's mission of delivering antibody-based therapies to protect vulnerable populations from viral infectious diseases, particularly SARS-CoV-2. A live webcast of the presentation will be accessible on the company's investor website and archived for 90 days post-event.

Invivyd is focused on developing a pipeline of high-quality, long-lasting antibodies to combat serious viral threats, starting with COVID-19 and extending to influenza and other significant diseases. For more information, visit invivyd.com.

Invivyd, Inc. (Nasdaq: IVVD) announced the FDA's clearance of its IND application for VYD222, a monoclonal antibody candidate aimed at preventing COVID-19 in vulnerable populations. The ongoing Phase 1 trial in Australia has completed dosing of the first cohort, moving to the second cohort, with initial readouts expected in Q2 2023. This trial is designed to evaluate safety, tolerability, and neutralizing activity against emerging variants. VYD222 is targeted at immunocompromised individuals who may not respond adequately to COVID-19 vaccines. The drug has shown in vitro neutralizing activity against the XBB.1.5 variant. Regulatory discussions are also underway for the pivotal trial design.

Invivyd, Inc. (Nasdaq: IVVD) announced the appointment of Robert Allen as chief scientific officer and Stacy Price as chief technology and manufacturing officer. Dr. Allen, with over 30 years of experience in infectious diseases, will lead the company's scientific direction and help develop therapies across Invivyd's pipeline, particularly focusing on antibodies for COVID-19 variants. Stacy Price, who joined Invivyd in March 2023, brings extensive biotechnology operations experience and will enhance the company's chemistry, manufacturing, and controls programs. Invivyd aims to deliver antibody-based therapies to protect vulnerable populations from serious viral diseases, including COVID-19 and influenza. CEO David Hering emphasized the strategic importance of these appointments for strengthening Invivyd's capabilities and advancing its product candidates.

Invivyd, Inc. (Nasdaq: IVVD) announced the initiation of a Phase 1 clinical trial for its monoclonal antibody candidate, VYD222, aimed at addressing COVID-19 in vulnerable populations. This randomized, placebo-controlled trial, featuring three IV infusion doses, will assess safety and pharmacokinetics. Preliminary data is expected in Q2 2023, with further clinical insights anticipated throughout the year. The trial is crucial as current authorized treatments show reduced efficacy against emerging SARS-CoV-2 variants. VYD222 has demonstrated in vitro activity against variants like XBB.1.5, providing hope for immunocompromised individuals who may not respond adequately to vaccination.

Invivyd, Inc. (Nasdaq: IVVD) announced it is advancing VYD222 into clinical development, demonstrating neutralizing activity against key COVID-19 variants. In 2022, the company reported a net loss of $241.3 million and expects its cash reserves of $372 million to support operations into the second half of 2024. The focus on VYD222 aims to fulfill the urgent need for effective therapies for vulnerable populations. This follows a strategic pivot to monoclonal antibody candidates as regulatory landscapes evolve. A conference call scheduled for March 23, 2023, will further detail these developments.

Invivyd, Inc. (Nasdaq: IVVD) announces the publication of research in Science Translational Medicine, detailing a model for evaluating monoclonal antibody (mAb) efficacy against symptomatic COVID-19. The Phase 2/3 study of adintrevimab indicates that low neutralizing antibody titers can provide clinically meaningful protection. This work is expected to influence regulatory frameworks for mAbs, potentially expediting development processes. The study identifies a protective titer threshold of 1:30, with higher levels enhancing protection. Invivyd plans to advance its candidate VYD222 into clinical trials soon, aiming to address evolving variants.